ES2124533T3 - Anticuerpos monoclonales inmunoestimulantes. - Google Patents

Anticuerpos monoclonales inmunoestimulantes.

Info

Publication number
ES2124533T3
ES2124533T3 ES95910891T ES95910891T ES2124533T3 ES 2124533 T3 ES2124533 T3 ES 2124533T3 ES 95910891 T ES95910891 T ES 95910891T ES 95910891 T ES95910891 T ES 95910891T ES 2124533 T3 ES2124533 T3 ES 2124533T3
Authority
ES
Spain
Prior art keywords
immunostimulant
monoclonal antibodies
anumals
carriing
bindes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95910891T
Other languages
English (en)
Inventor
Britta Hardy
Avraham Novogrodsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mor Research Applications Ltd
Original Assignee
Mor Research Applications Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mor Research Applications Ltd filed Critical Mor Research Applications Ltd
Application granted granted Critical
Publication of ES2124533T3 publication Critical patent/ES2124533T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Detergent Compositions (AREA)

Abstract

UN ANTICUERPO MONOCLONAL QUE TIENE EFECTOS DE INMUNOESTIMULACION SE UNE ESPECIFICAMENTE A CELULAS LINFOBLASTOIDES B E INDUCE LA PROLIFERACION Y ACTIVACION DE LINFOCITOS DE SANGRE PERIFERICOS, Y CUANDO SE INYECTA EN ANIMALES PORTADORES DE TUMORES PROVOCA UN EFECTO ANTI-TUMOR.
ES95910891T 1994-01-31 1995-01-30 Anticuerpos monoclonales inmunoestimulantes. Expired - Lifetime ES2124533T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL10850194A IL108501A (en) 1994-01-31 1994-01-31 Antibodies and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
ES2124533T3 true ES2124533T3 (es) 1999-02-01

Family

ID=11065761

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95910891T Expired - Lifetime ES2124533T3 (es) 1994-01-31 1995-01-30 Anticuerpos monoclonales inmunoestimulantes.

Country Status (20)

Country Link
US (1) US5897862A (es)
EP (1) EP0742795B1 (es)
JP (1) JP3478398B2 (es)
CN (1) CN1052733C (es)
AT (1) ATE171461T1 (es)
AU (1) AU693526B2 (es)
CA (1) CA2182289C (es)
DE (1) DE69504955T2 (es)
DK (1) DK0742795T3 (es)
EE (1) EE03285B1 (es)
ES (1) ES2124533T3 (es)
FI (1) FI963004A7 (es)
IL (1) IL108501A (es)
LT (1) LT4225B (es)
LV (1) LV11624B (es)
MD (1) MD1374G2 (es)
MX (1) MX9603080A (es)
NO (1) NO317020B1 (es)
RU (1) RU2155190C2 (es)
WO (1) WO1995020605A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2145634C1 (ru) * 1998-03-12 2000-02-20 Булычева Татьяна Ивановна Штамм культивируемых клеток мышиной гибридомы, используемый для получения моноклональных антител к ядрышковому антигену, ассоциированному с клеточной пролиферацией
IL129299A0 (en) * 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
RU2192888C1 (ru) * 2001-02-15 2002-11-20 Эпштейн Олег Ильич Лекарственное средство и способ лечения патологического синдрома
CN1294148C (zh) * 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
DE10311248A1 (de) * 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
HRP20120845T1 (hr) * 2003-07-02 2012-11-30 Innate Pharma Protutijela za pan-kir2dl nk-receptor i njihova uporaba u dijagnostici i lijeäśenju
WO2006021955A2 (en) * 2004-08-23 2006-03-02 Mor Research Applications Ltd. Use of bat monoclonal antibody for immunotherapy
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
PT2242773T (pt) * 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
MD3972C2 (ro) * 2009-03-11 2010-07-31 Ион МЕРЕУЦЭ Remediu şi metodă de tratament al stărilor precanceroase
US8686119B2 (en) 2011-07-24 2014-04-01 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
US9580504B1 (en) 2013-11-07 2017-02-28 Curetech Ltd. Pidilizumab monoclonal antibody therapy following stem cell transplantation
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
PE20231958A1 (es) 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗ｐｄ−１抗体及びその使用方法
BR112018006237A2 (pt) 2015-09-29 2018-10-09 Celgene Corp proteínas de ligação a pd-1 e métodos de uso das mesmas
PT3370768T (pt) 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
CN108367069B (zh) 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3515944A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHOD FOR TREATING IMMUNE DISEASES USING PD-1 BINDING PROTEINS
EP3515943A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
CN110300599B (zh) 2016-12-07 2024-07-02 艾吉纳斯公司 抗体和其使用方法
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182368A (en) * 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation

Also Published As

Publication number Publication date
MD1374F2 (en) 1999-12-31
NO963168D0 (no) 1996-07-29
FI963004A0 (fi) 1996-07-29
AU693526B2 (en) 1998-07-02
DE69504955D1 (de) 1998-10-29
IL108501A (en) 1998-10-30
JP3478398B2 (ja) 2003-12-15
US5897862A (en) 1999-04-27
EE03285B1 (et) 2000-08-15
LV11624B (en) 1997-06-20
WO1995020605A1 (en) 1995-08-03
CA2182289C (en) 2003-10-21
AU1868695A (en) 1995-08-15
NO963168L (no) 1996-09-27
EP0742795A1 (en) 1996-11-20
LV11624A (en) 1996-12-20
CN1052733C (zh) 2000-05-24
DK0742795T3 (da) 1999-06-14
LT96115A (en) 1997-05-26
CA2182289A1 (en) 1995-08-03
EP0742795B1 (en) 1998-09-23
FI963004L (fi) 1996-09-27
DE69504955T2 (de) 1999-05-27
CN1145077A (zh) 1997-03-12
NO317020B1 (no) 2004-07-26
ATE171461T1 (de) 1998-10-15
LT4225B (en) 1997-10-27
IL108501A0 (en) 1994-05-30
FI963004A7 (fi) 1996-09-27
MX9603080A (es) 1998-01-31
JPH09508390A (ja) 1997-08-26
RU2155190C2 (ru) 2000-08-27
MD1374G2 (ro) 2000-09-30

Similar Documents

Publication Publication Date Title
MX9603080A (es) Anticuerpos monoclonales inmuno-estimulantes.
EP0597829A4 (en) MONOCLONAL ANTIBODIES AGAINST A NEW ANTIQUE ASSOCIATED WITH HUMAN TUMORS.
DE68914244D1 (de) Monoklonaler Antikörper.
DE69319662D1 (de) Monoklonale Antikörper gegen GP130-Protein
PT796280E (pt) Anticorpo monoclonal 3h1 anti-idiotipico dos murinos
FI913891A7 (fi) Uusi monoklonaalinen vasta-aine uutta antigeenia vastaan, joka liittyy ihmisen kasvaimiin
DE3854502D1 (de) Gegen hiv-antigene spezifischer monoklonaler antikörper.
NO162179C (no) Monoklonale antistoffer for anvendelse in vitro.
OA08485A (fr) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas.
DK0474691T3 (da) Monoklonale antistoffer til induktion af tolerance
FI830573A7 (fi) Syövän diagnoosissa ja hoidossa hyödylliset vasta-aineet ja antigeenit.
DE3788148D1 (de) Monoklonale Antikörper und deren Verwendung.
DE3586216D1 (de) Brusttumorassoziiertes antigen und monoklonale antikoerper dazu.
EP0109434A4 (en) IN VITRO DIAGNOSTICS METHODS USING MONOCLONAL ANTIBODIES AGAINST PROTEINS OF CONNECTIVE TISSUES.
NO894444L (no) Anti-fucosylceramid monoklonalt antistoff.
ID20117A (id) Antibodi anti-fas
DE3580482D1 (de) Monoklonale antikoerper und immunisierung damit.
NO890116L (no) Monoklonale antistoffer.
DE3785795D1 (de) Monoklonale anti-menschliche magenkrebs-antikoerper.
EP0229107A4 (en) PROTECTIVE HUMAN MONOCLONAL ANTIBODIES TO -i(PSEUDOMONAS AERUGINOSA) EXOTOXIN A.
DE69023717D1 (de) Monoklonaler Antikörper.
FI893928A7 (fi) Monoklonala motkroppar.
ATE263784T1 (de) Anti-megakaryozyten monoklonaler antikörper 97a6
FI925638A7 (fi) Kasvainten yhteydessä esiintyvää antigeenia vastaan suunnattu monoklonaalinen vasta-aine 88BV59
NO903788D0 (no) Monoklonalt antistoff mot protein c.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 742795

Country of ref document: ES